IMRX
Immuneering Corporation [IMRX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
IMRX Stock Summary
Top IMRX Correlated Resources
IMRX
Top 10 Correlated ETFs
IMRX
Top 10 Correlated Stocks
IMRX
In the News
IMRX Financial details
Company Rating
-
Market Cap
61.49M
Income
1.02B
Revenue
94.42M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
68
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
0.19
Forward P/E
-
PEG
-0
P/S
2.08
P/B
1.89
P/C
-
P/FCF
-3.99
Quick Ratio
17.3
Current Ratio
17.89
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
38.78
EPS next Y
-
EPS next Q
-
EPS this Y
0.53%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
42.5%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
20.93%
-
-
-
-
SMA20
100%
SMA50
100%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
900%
ROE
960%
ROC
-0.52%
Gross Margin
-67%
Oper. Margin
-59%
Profit Margin
1085%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.9-14.29
52W High
-80.21%
52W Low
+177%
RSI
70
Rel Volume
20.44
Avg Volume
663.02K
Volume
13.55M
Perf Week
30.66%
Perf Month
132.77%
Perf Quarter
27.06%
Perf Half Y
60.12%
-
-
-
-
Beta
-0.894
-
-
Volatility
0.41%, 0.45%
Prev Close
0%
Price
2.77
Change
33.49%
Company Profile
- Volume Average 663.02K
- Market Capitalization 61.49M
- Employee 68
- CEO Dr. Benjamin J. Zeskind M.B.A., Ph.D.
- Headquarters Cambridge,MA,US
- IPO Date 2021-07-30
-
Website
https://immuneering.com 
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
